# US 2011/0257093 A1 · Therapies for acute renal failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257093 A1
- Document ID: US20110257093A1
- Status: Published application
- Kind: A1
- Application number: 13/079,161
- Filed: 2011-04-04
- Published: 2011-10-20
- Earliest claimed: 1997-05-05
- Assignees: Stryker Corporation
- Inventors: Charles M. Cohen; Kuber T. Sampath; Slobodan Vukicevic
- Web page: https://patentgrep.com/patent/US20110257093A1

## CPC

- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins.

## Claims

### Claim 1

A method for treating a mammal in, or at risk of, acute renal failure comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent.

### Claim 2

A method for treating a mammal to delay the need for, or reduce the frequency of, dialysis treatments of said mammal, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2 wherein said OP/BMP renal therapeutic agent is selected from the group consisting of a pro form, a mature form, and a soluble form of a polypeptide, wherein said polypeptide is selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9.

### Claim 6 (depends on 5)

The method of claim 5 wherein said OP/BMP renal therapeutic agent is selected from the group consisting of a pro form, a mature form, and a soluble form of OP-1.

### Claim at position 6

7-18. (canceled)

### Claim 19 (depends on 1, 2)

The method of claim 1 or 2 wherein said mammal is afflicted with a condition selected from the group consisting of pre-renal causes of acute renal failure, post-renal causes of acute renal failure, and intrinsic renal causes of acute renal failure.

### Claim 20 (depends on 19)

The method of claim 19 wherein said mammal is afflicted with a pre-renal cause of acute renal failure selected from the group consisting of decreased cardiac output, hypovolemia, volume redistribution, and altered vascular resistance.

### Claim 21 (depends on 19)

The method of claim 19 wherein said mammal is afflicted with a post-renal cause of acute renal failure selected from the group consisting of ureteral, pelvic and bladder obstructions.

### Claim 22 (depends on 19)

The method of claim 19 wherein said mammal is afflicted with an intrinsic renal cause of acute renal failure selected from the group consisting of abnormalities of the vasculature, abnormalities of the glomeruli, acute interstitial nephritis, intratubular obstruction, and acute tubular necrosis.

### Claim 23 (depends on 1)

The method of claim 1 wherein said mammal is a kidney transplant recipient.

### Claim 24

(canceled)

### Claim 25 (depends on 1, 2)

The method of claim 1 or 2 wherein said administration is selected from oral, parenteral, intravenous, intraperitoneal, or into the renal capsule.

### Claim at position 14

26-29. (canceled)

### Claim 30 (depends on 25)

The method of claim 25 wherein a stent has been implanted into said mammal for said administration.

### Claim 31 (depends on 30)

The method of claim 30 wherein said stent is selected from an intravenous stent, an intraperitoneal stent, or a renal intracapsular stent.

### Claim at position 17

32-36. (canceled)

### Claim 37 (depends on 1, 2)

The method of claim 1 or 2 wherein said renal therapeutic agent is administered at a dosage of about 0.01-1000 μg/kg body weight of said mammal or 0.1-100 μg/kg body weight of said mammal.

### Claim at position 19

38-52. (canceled)
